As shown in Table 5, overexpression of MEX3A, MEX3B, MEX3C and MEX3D was associated with a significantly lower OS of NSCLC and LUAD patients, while overexpression of MEX3D was associated with significantly worse OS among patients with LUSC. Here, MEX3B is linked to non-small cell lung carcinoma.